Table 1.
Seven previous reports and 2 episodes of neurotoxicity and nephrotoxicity in our patient caused by combined use of lithium and risperidone
| R.N. | Age | Sex | Diagnosis | Risperidone dose (mg) | Lithium dose (mg) | Time to onseta | Clinical presentation | Laboratory values and Image |
|---|---|---|---|---|---|---|---|---|
| [3] | 69 | F | BD | 6 | 450 | 3 weeks | Delirium | Cr: NA; Li: 1.36 |
| [4] | 30 | M | BD | NA | 900 | 1 week | NMS | Cr: 1.6; Li: 0.6; CPK: 1428 |
| [5] | 46 | M | NA | 3 | 900 | 2 years | NMS, DKA | BUN: 66 |
| [6] | 54 | F | BD | 3 | 1500 | 2 months | NMS | Cr: NA; Li: 0.7; CPK: 791 |
| [7] | 60 | F | SD | 6 | NA | 3 weeks | Delirium | EEG: Abnormal; CK: 953 |
| [8] | 75 | M | BD | 2 | 900 | 4 days | Lethargy | EEG: Abnormal; Cr: NA; Li: 1.47 |
| [9] | 60 | F | SD | 6 | NA | 6 days | NMS | EEG: Abnormal; CPK: 953 |
| Ib | 56 | M | SD | 4.5c | 900 | 12 days | Delirium | BUN/Cr: 24/1.33; Li: 1.42; CK: 975 |
| IIb | 3 | 600 | 3 days | Delirium | BUN/Cr: 29/1.36; Li: 1.54; CK: 90 |
aTime is calculated from beginning the combination of lithium and risperidone to the occurrence of adverse events
bI and II are serial numbers of the 2 episodes of our patient during hospitalization
cIM Risperidone 25 mg/vial was prescribed 7 days before oral risperidone